recently cloned TSC1 gene has 23 exons spanning some 40 kb of genomic DNA with an 8.6 kb transcript. We now report the results ofmutation screening by SSCP and heteroduplex analysis of genomic DNA for all 21 coding exons of TSC1 in 83 unrelated cases of tuberous sclerosis.
TSC1 gene mutations were found in 16 of the 83 cases (19%). These comprised base substitutions, small insertions, or small deletions giving rise to six nonsense mutations, eight frameshifts, and two splice site mutations, all ofwhich would be expected to result in a truncated or absent protein. In the 10 cases predicted to have TSC1 mutations by linkage analysis or loss of heterozygosity studies, the mutation was identified in eight (80%). In the remaining 73 unassigned cases, only eight mutations were found (11%). From these data we estimate that TSC1 mutations accounted for 24% of the cases in this sample (and an Reaction volumes were halved as compared to ABI protocols. All mutations were confirmed on the opposite strand and from a second PCR product. Mutations were numbered according to the published cDNA sequence." 11 %. From these data we estimate that TSC 1 mutations account for 24% of the patients tested and 22% of the whole patient panel including cases with TSC2 mutations. The overall detection rate in familial cases was 35% as compared to 13% in sporadic cases, but the difference did not reach statistical significance (Fisher's exact p value=0.06).
Discussion
We have reported the results of mutation screening of the TSC1 gene in 83 unrelated cases of tuberous sclerosis using SSCP and heteroduplex analysis to test all 21 coding exons amplified from genomic DNA. Mutations were detected in 19% of the patients tested (representing 17% of the whole patient panel including cases with TSC2 mutations). This is comparable to the study by Jones et a122 who identified mutations in 13% of their patients using a similar approach. The mutations were either single base substitutions, small deletions, or insertions giving rise to nonsense mutations, frameshifts, or aberrant splicing. This is similar to the mutation spectrum reported by others. '7 22 Three-quarters of the mutations identified were novel changes only observed in a single family and these data bring to 54 the total number of different mutations reported. ' 16 The identification of the TSC1 gene is an important step in providing a molecular genetic diagnostic service for families affected by TSC. However, screening of 21 exons amplified from genomic DNA is labour intensive and analysis of TSC1 mRNA may be a more efficient approach. Since most TSC 1 mutations are truncating, the analysis of TSCl mRNA by PTT might provide an effective mutation screening strategy. We have previously shown that mutations can be detected in the TSC2 gene by analysis of mRNA using the protein truncation test (PT-T).9
In developing protocols for mutation screening, important considerations are mutation detection rates and the frequencies of TSC 1 and TSC2 mutations in familial and sporadic cases. In the current study, there were 10 cases predicted to have TSC1 mutations by linkage analysis or loss of heterozygosity studies and eight mutations were identified, giving an estimated mutation detection rate for TSC 1 mutants of 80%. This would be comparable to the detection rates achieved with SSCP/ heteroduplex analysis in studies of other genes. On the assumption that the same detection rate applies to the unassigned cases where another eight mutations were found, we would estimate that two TSC1 mutations were missed. This would give an estimated 20 TSC1 mutants in the sample of 83 patients, representing 24% of the patients tested and 22% of the whole patient panel including cases with TSC2 mutations. This is at odds with the data from linkage studies suggesting that TSC 1 and TSC2 contribute equally to familial cases of tuberous sclerosis.3 In the Consortium paper, the mutation detection rate in patients predicted to have TSC 1 mutations by linkage analysis was also substantially higher than in unassigned cases.'7 Jones et at2' reported a significant under-representation of TSC 1 mutations in sporadic cases, finding mutations in 37% (9/24) of familial cases as compared to 9% (13/147) of sporadic cases. To account for this, they suggested that the mutation rate in the TSC2 gene is higher than in TSC1, but mutations in TSC2 are associated with a lower reproductive fitness, giving rise to more equal representation in families. In the present study, the comparable figures for TSC 1 mutation detection were 35% (8/23) in familial cases and 13% (8/60) in sporadic cases (table 3) , showing the same trend but failing to reach statistical significance. More data will be needed to determine whether the under-representation of TSC1 mutations is confined to sporadic cases or also applies to families.
